newsfilter
← Latest News
GlobeNewswire·

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the pricing of its